Health claims made in vape shops: an observational study and content analysis.
advertising and promotion
electronic nicotine delivery systems (ENDS)
surveillance and monitoring
Journal
Tobacco control
ISSN: 1468-3318
Titre abrégé: Tob Control
Pays: England
ID NLM: 9209612
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
04
06
2018
revised:
22
01
2019
accepted:
24
01
2019
pubmed:
28
5
2019
medline:
26
6
2020
entrez:
25
5
2019
Statut:
ppublish
Résumé
Prior to the final deeming rule, federal law in the USA prohibited electronic cigarettes (e-cigarettes) from being marketed as smoking cessation products; for other therapeutic purposes and in ways that conveyed Food and Drug Administration (FDA) approval/endorsement. After August 2016, additional federal prohibitions were added including false/misleading and unauthorised modified risk tobacco product (MRTP) claims. No systematic investigation of e-cigarette health claims has been conducted in the retail environment. We sought to document and characterise claims made in vape shops. Between November 2015 and February 2016, before final deeming rule implementation, two trained data collectors conducted unannounced observational assessments of 46 vape shops in North Carolina. Data collectors used wearable imaging technology to document health claims about e-cigarettes. Photos were coded for five claim types: (1) cessation device; (2) drug effect/device; (3) FDA-approved/endorsed; (4) false/misleading and (5) MRTP. Photos were double coded; differences between coders were adjudicated and reviewed by an expert panel. At least one health claim was displayed in 41.3% (n=19) of retailers, ranging from 0 to 27 claims per retailer. All claim types were found. Cessation device claims were the most prevalent (62.2%, n=84), followed by MRTP (27.4%, n=37), drug effect/device (8.1%, n=11), false/misleading (1.5%, n=2), and FDA approved/endorsed (0.7%, n=1). Retail chains made the majority of claims compared with independent shops (88.9% vs 11.1%). Many vape shops displayed e-cigarette health claims, which are all now FDA prohibited. These claims could mislead consumers and influence behaviour. Findings highlight the need for retailer education, continued surveillance, enforcement specific to advertising and research on consumer perceptions of claims.
Sections du résumé
BACKGROUND
Prior to the final deeming rule, federal law in the USA prohibited electronic cigarettes (e-cigarettes) from being marketed as smoking cessation products; for other therapeutic purposes and in ways that conveyed Food and Drug Administration (FDA) approval/endorsement. After August 2016, additional federal prohibitions were added including false/misleading and unauthorised modified risk tobacco product (MRTP) claims. No systematic investigation of e-cigarette health claims has been conducted in the retail environment. We sought to document and characterise claims made in vape shops.
METHODS
Between November 2015 and February 2016, before final deeming rule implementation, two trained data collectors conducted unannounced observational assessments of 46 vape shops in North Carolina. Data collectors used wearable imaging technology to document health claims about e-cigarettes. Photos were coded for five claim types: (1) cessation device; (2) drug effect/device; (3) FDA-approved/endorsed; (4) false/misleading and (5) MRTP. Photos were double coded; differences between coders were adjudicated and reviewed by an expert panel.
RESULTS
At least one health claim was displayed in 41.3% (n=19) of retailers, ranging from 0 to 27 claims per retailer. All claim types were found. Cessation device claims were the most prevalent (62.2%, n=84), followed by MRTP (27.4%, n=37), drug effect/device (8.1%, n=11), false/misleading (1.5%, n=2), and FDA approved/endorsed (0.7%, n=1). Retail chains made the majority of claims compared with independent shops (88.9% vs 11.1%).
CONCLUSIONS
Many vape shops displayed e-cigarette health claims, which are all now FDA prohibited. These claims could mislead consumers and influence behaviour. Findings highlight the need for retailer education, continued surveillance, enforcement specific to advertising and research on consumer perceptions of claims.
Identifiants
pubmed: 31123104
pii: tobaccocontrol-2018-054537
doi: 10.1136/tobaccocontrol-2018-054537
pmc: PMC8142343
mid: NIHMS1690592
doi:
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e119-e125Subventions
Organisme : NCI NIH HHS
ID : P50 CA180907
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Fed Regist. ;82(5):2193-217
pubmed: 28071877
Tob Control. 2016 Mar;25(2):188-94
pubmed: 25335902
Nicotine Tob Res. 2018 Sep 25;20(11):1353-1358
pubmed: 28651376
Nicotine Tob Res. 2014 Aug;16(8):1150-5
pubmed: 24847099
Ethn Health. 2013;18(2):136-51
pubmed: 22789035
Int J Environ Res Public Health. 2015 May 15;12(5):5215-32
pubmed: 25988311
Tob Regul Sci. 2016 Jul;2(3):252-262
pubmed: 27446984
Health Place. 2014 Jul;28:38-44
pubmed: 24742811
Chem Res Toxicol. 2015 Aug 17;28(8):1532-7
pubmed: 26158618
MMWR Morb Mortal Wkly Rep. 2016 Jun 10;65(22):557-61
pubmed: 27281058
Tob Induc Dis. 2017 Jun 17;15:28
pubmed: 28638314
Nicotine Tob Res. 2016 Apr;18(4):453-9
pubmed: 25863521
Tob Control. 2001;10 Suppl 1:i12-6
pubmed: 11740039
Nicotine Tob Res. 2016 Oct;18(10):2006-12
pubmed: 27029821
Curr Environ Health Rep. 2015 Dec;2(4):423-9
pubmed: 26452675
Prev Chronic Dis. 2016 May 19;13:E68
pubmed: 27197081
Fed Regist. 2016 May 10;81(90):28973-9106
pubmed: 27192730
Tob Prev Cessat. 2016;2(Suppl):
pubmed: 28725875
Drug Alcohol Depend. 2016 Jun 01;163:134-40
pubmed: 27125661
Int J Environ Res Public Health. 2018 Jun 06;15(6):
pubmed: 29882828
Nicotine Tob Res. 2018 Jul 9;20(8):1020-1024
pubmed: 29059443
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):597-603
pubmed: 28617771
Am J Prev Med. 2013 Oct;45(4):462-73
pubmed: 24050423
MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):381-5
pubmed: 25879896
Am J Public Health. 2013 Oct;103(10):1902-9
pubmed: 23948008
Am J Health Behav. 2015 Nov;39(6):794-8
pubmed: 26450547
Tob Control. 2013 Sep;22(5):349-55
pubmed: 22491038
Am J Public Health. 2015 Jun;105(6):e16-21
pubmed: 25880960
Tob Prev Cessat. 2017;2(Suppl):
pubmed: 29057379
Nicotine Tob Res. 2002;4 Suppl 2:S147-55
pubmed: 12573176
Tob Induc Dis. 2014 Nov 28;12(1):22
pubmed: 25484852
Am J Prev Med. 2014 Apr;46(4):395-403
pubmed: 24650842
Addiction. 2015 Aug;110(8):1352-6
pubmed: 25996087
Pediatrics. 2004 Oct;114(4):e445-51
pubmed: 15466070
Drug Alcohol Depend. 2014 Jan 1;134:309-313
pubmed: 24309296
Nicotine Tob Res. 2016 May;18(5):694-9
pubmed: 26113622
Am J Prev Med. 2012 Feb;42(2):150-6
pubmed: 22261211
Tob Control. 2001;10 Suppl 1:i24-32
pubmed: 11740041